生血宁片辅助放化疗对肺癌术后患者T淋巴细胞亚群及IL-23、IL-17水平的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (471 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the influence of Shengxuening Tablets adjuvant chemotherapy on T lymphocyte subsets and interleukin-23 (IL-23) and interleukin-17 (IL-17) levels of postoperative patients with lung cancer. Methods Ninety-two cases of postoperative patients with lung cancer treated in Affiliated Hospital of Chengde Medical University from October 2015 to January 2017 were selected as the study objects, and they were divided into observation group and control group according to random number table method, with 46 cases in each group. The control group was given concurrent chemoradiotherapy, and the observation group was added with Shengxuening Tablets on the basis of the control group. After treatment, the clinical efficacy was evaluated, and the peripheral blood, immune function, levels of IL-23 and IL-17, and the incidence of adverse reactions were observed in the two groups. Results The total effective rate of the observation group (73.91%) was significantly higher than that of the control group (52.17%) (P ＜ 0.05). After treatment, the platelets, leukocytes, neutrophils in the two groups were significantly lower than those before treatment (P ＜ 0.05), and those in the observation group were significantly lower than those in the control group (P ＜ 0.05). There was no significant difference of hemoglobin before and after treatment (P ＞ 0.05). There were no significant differences of the levels of CD3+, CD4+ and CD8+ in the observation group before and after treatment (P ＞ 0.05), while the level of CD4+/CD8+ in the observation group after treatment was significantly lower than that before treatment (P ＜ 0.05). After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the control group were significantly lower than those before treatment (P ＜ 0.05), the level of CD8+ was significantly higher than that before treatment (P ＜ 0.05). After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group (P ＜ 0.05), and the level of CD8+ was significantly lower than that in the control group (P ＜ 0.05). After treatment, the levels of IL-23 and IL-17 in the two groups were all significantly lower than those before treatment (P ＜ 0.05), which in the observation group were significantly lower than those in the control group (P ＜ 0.05). There was no serious liver and kidney dysfunction, and there was no significant differences in the incidence of radiation pneumonitis and radiation esophagitis between the two groups (P ＞ 0.05). The incidence of gastrointestinal reactions and myelosuppression in the observation group was significantly lower than that in the control group (P ＜ 0.05). Conclusion Shengxuening Tablets adjuvant chemotherapy can effectively improve peripheral blood and T lymphocyte subsets, reduce the levels of IL-23, IL-17 and the incidence of adverse reactions, which can improve clinical efficacy.

Key words： Shengxuening Tablets Chemotherapy Lung cancer Interleukin-23 Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Tong RAO Jingfen LIU Chengyi ZHAO Shuang ZHANG Li

Cite this article:

ZHU Tong RAO Jingfen LIU Chengyi ZHAO Shuang ZHANG Li. Influence of Shengxuening Tablets adjuvant chemotherapy on T lymphocyte subsets and IL-23 and IL-17 levels of postoperative patients with lung cancer[J]. 中国医药导报, 2018, 15(2): 87-91.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I2/87

[1] 孔谦.顺铂分别与吉西他滨、多西他赛联合治疗非小细胞肺癌的疗效对比[J].锦州医科大学学报，2017，38（1）：40-42.
[2] 姚榕，范瑞华，周磊磊，等.同步放化疗以及序贯放化疗治疗在肺癌患者治疗中的效果对比[J].中华肿瘤防治杂志，2016，23（S1）：122，142.
[3] 陈红，曾恩泉.生血宁治疗肿瘤相关性贫血的临床分析[J].川北医学院学报，2014，29（1）：76-78.
[4] 中国抗癌协会.新编常见恶性肿瘤诊治规范[M].北京：中国协和医科大学出版社，1999.
[5] 丁婕，戴旭，孟宪运，等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复，2015，22（9）：1150-1152.
[6] 余建云，李林均，陈萍，等.局部晚期非小细胞肺癌同步放化疗并序贯化疗与单纯序贯放化疗的对比研究[J].肿瘤防治研究，2015，42（6）：606-609.
[7] 贺明鸽.多西他赛与顺铂联合放疗治疗晚期肺癌的临床疗效比较分析[J].中国实用医药，2016，11（20）：167-168.
[8] 王俊斌，郑荣生，杨燕，等.乌苯美司联合化疗对晚期肺癌患者临床疗效和免疫功能的影响[J].免疫学杂志，2015， 31（7）：599-602.
[9] Robinson CG，Patel AP，Bradley JD，et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy：A review of the National Cancer Data Base [J]. J Clin Oncol，2015，33（8）：870-876.
[10] 祝沈冬，段宏燕，于清蕊.同步放化疗与序贯放化疗治疗Ⅲ期非小细胞肺癌的临床疗效比较[J].临床肺科杂志，2013，18（3）：415-416.
[11] 姬蕾，张桂琼，薛文翰，等.升血颗粒配合化疗对老年晚期非小细胞肺癌患者免疫功能的影响[J].河北中医，2017，39（2）：241-244，248.
[12] 辜斌，谢佳琳，林东亮，等.复方斑蝥胶囊对肺癌的疗效及其对免疫水平的影响[J].世界中医药，2016，11（12）：2649-2653.
[13] 杨忠明，曾瑞，王杰，等.加味六君子汤对肺癌术后化疗免疫功能的影响[J].成都医学院学报，2017，12（2）：166-169，174.
[14] 石磊，王丽丽，胡魁，等.沙参麦冬汤联合化疗对肺癌患者免疫功能的影响研究[J].中华中医药学刊，2015，33（6）：1363-1366.
[15] 滕春凤.王克穷合参腹诊辨识经方治疗肺癌一案[J].环球中医药，2016，9（4）：463-464.
[16] 何改平，张彬，张宝文，等.肺癌脑转移患者Th17细胞和IL-17水平变化的研究[J].中国肺癌杂志，2013，16（9）：476-481.
[17] 唐亮.玉屏风颗粒联合百令胶囊对肺癌化疗患者免疫功能的调节作用[J].现代中西医结合杂志，2015，24（12）：1318-1319.
[18] 王晓莉，张鲁明，蒋陆霞，等.加味金水六君煎对肺癌患者围手术期的免疫调节及临床疗效研究[J].世界中医药，2016，11（9）：1798-1802.
[19] 梁秋萍，殷俊.EGFR TKI+TP方案及TP方案对晚期非小细胞肺癌治疗临床效果及肿瘤标志物水平的影响[J].成都医学院学报，2016，11（1）：40-44.
[20] 戴春.血清中炎症相关细胞因子与非小细胞肺癌关系的研究[D].昆明：昆明医科大学，2015.